Lung Cancer Trial, Recruiting NCT07384897 Sponsor: Université Catholique de Louvain Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT07384897
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with lung cancer
  • You have been found to have pre-cancerous growths in your lungs
  • You have a long-term inflammatory lung condition (such as sarcoidosis or COPD) and have not yet started treatment for it
  • You are a healthy individual with no known lung disease (as part of a comparison/control group)
  • You are a child or teenager weighing at least 10 kg (about 22 lbs) who has been confirmed through genetic testing to have a condition called chronic granulomatous disease (CGD)
  • You are an adult who is already scheduled for bone surgery during which a bone marrow sample will be collected

Who may not be able to join:

  • You are taking steroid medications (such as prednisone) at a dose of more than 10 mg per day, or an equivalent amount of a similar medication
  • You currently have an active infection at the time of enrollment
  • You are unable or unwilling to give your consent to take part in the trial (or, if applicable, to give your agreement alongside a parent or guardian's consent)
  • You have a long-term inflammatory lung condition that is currently being treated with medications that suppress the immune system

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Frank Aboubakar Nana, MD; PhD, Cliniques universistaires saint Luc

Phone: 0032 2 764 85 19

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Université Catholique de Louvain
Registry
ClinicalTrials.gov
Start date
17 February 2025
Est. completion
1 December 2030

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Progression free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov